Jean M. Hobby Sells 11,960 Shares of Integer Holdings Co. (NYSE:ITGR) Stock

Integer Holdings Co. (NYSE:ITGR) Director Jean M. Hobby sold 11,960 shares of the business’s stock in a transaction that occurred on Wednesday, July 31st. The shares were sold at an average price of $119.66, for a total transaction of $1,431,133.60. Following the transaction, the director now directly owns 2,280 shares in the company, valued at $272,824.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Integer Price Performance

Shares of ITGR stock traded down $2.60 during trading hours on Thursday, reaching $116.16. 364,971 shares of the company were exchanged, compared to its average volume of 332,962. Integer Holdings Co. has a fifty-two week low of $69.40 and a fifty-two week high of $130.15. The company has a debt-to-equity ratio of 0.73, a current ratio of 3.29 and a quick ratio of 1.96. The stock’s fifty day moving average is $118.96 and its two-hundred day moving average is $113.66. The company has a market cap of $3.89 billion, a price-to-earnings ratio of 40.19, a P/E/G ratio of 1.77 and a beta of 1.11.

Integer (NYSE:ITGR) last announced its quarterly earnings data on Thursday, July 25th. The medical equipment provider reported $1.30 EPS for the quarter, beating analysts’ consensus estimates of $1.24 by $0.06. The firm had revenue of $436.20 million for the quarter, compared to analyst estimates of $437.00 million. Integer had a return on equity of 11.48% and a net margin of 6.31%. The business’s quarterly revenue was up 9.0% compared to the same quarter last year. During the same period last year, the company earned $1.14 EPS. Sell-side analysts forecast that Integer Holdings Co. will post 5.31 earnings per share for the current fiscal year.

Analyst Ratings Changes

ITGR has been the topic of several research analyst reports. KeyCorp boosted their price target on shares of Integer from $123.00 to $139.00 and gave the company an “overweight” rating in a report on Tuesday, April 9th. Truist Financial began coverage on shares of Integer in a research note on Wednesday, May 15th. They issued a “buy” rating and a $137.00 target price for the company. Benchmark restated a “buy” rating and set a $130.00 price target on shares of Integer in a research note on Friday, May 10th. Oppenheimer began coverage on shares of Integer in a research note on Tuesday, July 16th. They issued an “outperform” rating and a $135.00 price objective for the company. Finally, Citigroup boosted their price target on Integer from $118.00 to $124.00 and gave the stock a “neutral” rating in a research report on Wednesday, May 22nd. Two equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $133.86.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the business. GAMMA Investing LLC boosted its stake in Integer by 60.9% in the second quarter. GAMMA Investing LLC now owns 375 shares of the medical equipment provider’s stock valued at $43,000 after acquiring an additional 142 shares during the last quarter. Blue Trust Inc. boosted its position in shares of Integer by 483.3% in the 4th quarter. Blue Trust Inc. now owns 455 shares of the medical equipment provider’s stock worth $45,000 after purchasing an additional 377 shares during the last quarter. Principal Securities Inc. bought a new stake in Integer in the fourth quarter valued at about $67,000. Headlands Technologies LLC bought a new stake in Integer in the first quarter valued at about $106,000. Finally, Innealta Capital LLC bought a new position in Integer during the second quarter worth about $110,000. Institutional investors own 99.29% of the company’s stock.

About Integer

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.